Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

PSO-BIO-COVID study group, M. Talamonti, M. Galluzzo, A. Chiricozzi, P. Quaglino, G. Fabbrocini, P. Gisondi, A.V. Marzano, C. Potenza, A. Conti, A. Parodi, S. Piaserico, F. Bardazzi, G. Argenziano, F. Rongioletti, L. Stingeni, G. Micali, F. Loconsole, M.T. Rossi, M.R. BongiornoC. Feliciani, P. Rubegni, P. Amerio, M.C. Fargnoli, P. Pigatto, P. Savoia, S.P. Nisticò, S. Giustini, A. Carugno, S.P. Cannavo’, G. Rech, F. Prignano, A. Offidani, M. Lombardo, I. Zalaudek, L. Bianchi, K. Peris

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)271-277
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume21
Issue number2
DOIs
Publication statusPublished - 2021

Keywords

  • biological therapy
  • COVID-19
  • dermatology
  • psoriasis
  • sars-CoV-2
  • biological product
  • IL23R protein, human
  • interleukin 17
  • interleukin receptor
  • tumor necrosis factor
  • adult
  • aged
  • chronic disease
  • clinical trial
  • cohort analysis
  • female
  • human
  • incidence
  • Italy
  • male
  • middle aged
  • multicenter study
  • pandemic
  • procedures
  • risk assessment
  • very elderly
  • young adult
  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Products
  • Biological Therapy
  • Chronic Disease
  • Cohort Studies
  • Female
  • Humans
  • Incidence
  • Interleukin-17
  • Male
  • Middle Aged
  • Pandemics
  • Psoriasis
  • Receptors, Interleukin
  • Risk Assessment
  • Tumor Necrosis Factor-alpha
  • Young Adult

Cite this